|1.||Sun, Yu-Nien: 12 articles (07/2011 - 06/2007)|
|2.||Hei, Yong-Jiang: 6 articles (08/2014 - 11/2010)|
|3.||Polverino, Anthony: 6 articles (01/2012 - 09/2006)|
|4.||Bass, Michael B: 5 articles (11/2014 - 06/2007)|
|5.||McCoy, Sheryl: 5 articles (08/2014 - 01/2011)|
|6.||Rosen, Lee S: 4 articles (11/2014 - 06/2007)|
|7.||Sun, Y-N: 4 articles (04/2014 - 11/2008)|
|8.||Ye, Yining: 4 articles (01/2014 - 01/2010)|
|9.||Coxon, Angela: 4 articles (01/2012 - 09/2006)|
|10.||Baerlocher, Gabriela M: 3 articles (12/2015 - 01/2010)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/01/2014 - "The motesanib phase III MONET1 study failed to show improvement in overall survival (OS) in non-small cell lung cancer, but a subpopulation of Asian patients had a favorable outcome. "
08/01/2014 - "Efficacy of motesanib diphosphate in non-small-cell lung cancer."
04/01/2014 - "Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results."
12/01/2012 - "Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study."
01/01/2014 - "We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. "
06/10/2007 - "Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors."
12/01/2013 - "The purpose of this study was to determine the recommended phase II dose of imetelstat in children with recurrent or refractory solid tumors. "
12/01/2013 - "A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112)."
01/01/2013 - "The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors."
10/01/2010 - "Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors."
|3.||Breast Neoplasms (Breast Cancer)
02/01/2015 - "The effects of imetelstat on CSC populations of HER2(+) breast cancer cells were measured by ALDH activity and CD44/24 expression by flow cytometry as well as mammosphere assays for functionality. "
01/01/2009 - "These data suggest that motesanib may have broad utility in the treatment of human breast cancer."
02/01/2015 - "The purpose of this study was to investigate the effects of a telomerase antagonistic oligonucleotide, imetelstat (GRN163L), on CSC and non-CSC populations of HER2(+) breast cancer cell lines. "
04/01/2011 - "We aimed to determine whether treatment with motesanib plus paclitaxel is better than placebo plus paclitaxel in patients with HER2-negative locally recurrent or metastatic breast cancer. "
01/01/2009 - "Treatment with motesanib alone or in combination with chemotherapy inhibits tumor growth in vivo in various models of human breast cancer. "
|4.||Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/01/2010 - "Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors."
04/01/2010 - "The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. "
04/01/2010 - "Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate."
07/01/2011 - "Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors."
07/01/2011 - "This multicenter phase 2 study assessed the tolerability and efficacy of motesanib, an oral inhibitor of Kit, platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptors (VEGFR), in patients with imatinib-resistant gastrointestinal stromal tumors (GIST). "
04/01/2013 - "Twenty-two eligible patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma were treated with an oral daily dose of 125 mg of motesanib. "
04/01/2013 - "A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study."
02/01/2009 - "Small molecule tyrosine kinase inhibitors, including sorafenib, sunitinib, motesanib and vandetanib, which have already shown efficacy against other neoplastic diseases, are being evaluated in clinical trials for treatment of thyroid carcinomas. "
|3.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|4.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|6.||Telomerase (Telomerase Reverse Transcriptase)
|8.||sorafenib (BAY 43-9006)
|9.||N- (4- bromo- 2- fluorophenyl)- 6- methoxy- 7- ((1- methylpiperidin- 4- yl)methoxy)quinazolin- 4- amine (ZD6474)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)